PDF
Citation
Print
INTRODUCTION
Graves’ disease (GD), a common autoimmune endocrinopathy, causes hyperthyroidism, which is characterized by excess production and secretion of thyroid hormones by the thyroid gland. The global prevalence of GD is approximately 0.5% [1,2], and its incidence is approximately 0.5–1.0 per 1,000 person-years [2,3]. GD is treated in three ways: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy with iodine-131 (131I), and thyroidectomy. Each of these three treatments has advantages and disadvantages, and none of them can be considered optimal in absolute terms [4,5]. ATD therapy is commonly used as the initial treatment of choice for GD, because it is the only treatment aiming to restore normal thyroid function [6]. Although the preferred initial treatment varies across countries and regions [7], an ATD is administered initially in 97% to 98% of Asian patients and 16% to 41% of American patients [3,7-10]. Recently, ATD as an initial treatment in United States has increased to almost 60% [11]. However, a low remission rate (40% to 50%) and a high recurrence rate are major limitations of ATD treatment [10]. Therefore, many patients do not achieve remission after ATD use and require a second-line treatment such as RAI therapy, surgery, or long-term ATD. Many patients in whom ATD treatment fails select RAI therapy because surgery is invasive and poses a risk of surgical complications, such as hypoparathyroidism and recurrent laryngeal nerve damage, whereas RAI therapy is less invasive and has fewer complications and lower costs. Previous studies reported that 46% to 77% of patients in whom ATD treatment failed selected RAI therapy [10,12].
The success rate of initial RAI therapy was reported to be 74% to 81% in a previous randomized controlled study [13], which is higher than that of ATD therapy. Nonetheless, the response rate of RAI is still limited, especially in patients with previous ATD use [14,15]. For this reason, some patients (6% to 10% of GD patients according to previous research) require repeated RAI therapy [10,16,17]. However, little is known about the clinical outcomes of additional rounds of RAI therapy. Therefore, in the present study, we investigated the clinical implications of repeated RAI therapy.
METHODS
Subject
In this retrospective study, GD patients who underwent RAI therapy as second-line therapy after the failure of ATD treatment at a single tertiary referral hospital between 2001 and 2015 were enrolled [18]. The diagnosis of GD was based on a clinical examination, typical alterations of the thyroid function test (high free thyroxine [T4] and/or high total triiodothyronine and low thyrotropin [TSH]), and the presence of TSH receptor (TSHR) antibody and/or diffusely increased thyroid uptake of 99m-Tc on radionuclide scintigraphy. Among 10,986 GD patients, 1,319 (12%) patients underwent RAI therapy were screened. Patients who started their initial RAI therapy before 2001 (n=115), who underwent thyroidectomy (n=114) before or after RAI therapy for reasons other than GD, who received RAI therapy as an initial treatment (n=5), or who had a follow-up duration of less than 1 year (n=122) were excluded. In addition, patients who received RAI therapy due to severe adverse events of ATDs such as agranulocytosis and toxic hepatitis (n=148) were excluded because their characteristics were significantly different from those of patients with ATD failure (Supplemental Table S1). Finally, 815 patients were enrolled in the analysis of the clinical outcomes of repeated RAI therapy for GD. The study was approved by the Institutional Review Board committee of Seoul National University Hospital (No. 1410-097-619). Informed consent was waived due to a retrospective nature of our study. Information regarding age, sex, the time of diagnosis, goiter size, ATD use history, and laboratory test results (TSH, free T4, and TSHR antibody) was obtained retrospectively by reviewing patients’ electronic medical records. In our hospital, the goiter sized was evaluated and recorded at the first visit for GD. The goiter size was assessed by the endocrinologists through physical examination (palpation).
Protocols for RAI therapy
Prior to RAI, ATDs were stopped for more than 7 days and iodine-rich food such as seaweed was avoided for 2 weeks according to the guidelines [4,9]. 131I was administered to patients at a fixed dose of 15 mCi (555 MBq). Thyroid radioactive iodine uptake (RAIU) was measured at 48 hours after oral administration of 131I. ATD was restarted 3 days later, if needed.
Definition of remission after RAI therapy
Remission was defined as (1) hypothyroid or euthyroid status without using an ATD or (2) a requirement for levothyroxine (LT4) at 12 months after RAI therapy. Otherwise, the disease was considered to be persistent.
Statistical analysis
Data were presented as the mean±standard deviation. To compare the characteristics of patients according to remission status, categorical and continuous variables were analyzed using the chi-square test or the Student t test. Kaplan-Meier curves for the discontinuation of ATD and the initiation of LT4 were plotted, and the curves of the 1st and 2nd RAI therapies were compared using the log-rank test. To investigate predictive factors for remission, univariate/multivariate logistic regression analysis was performed. P values <0.05 were considered to indicate statistical significance. All statistical analyses were performed using SPSS version 23.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
Higher remission rate of the second RAI therapy
In total, 815 patients underwent RAI therapy as second-line therapy after ATD failure. Their mean age was 41±13 years and 67% were women. The 1-year remission rate was 48% (393/815). Among the 422 (52%) patients who did not achieve remission, 230 patients underwent 2nd RAI therapy, with a median interval between the 1st and 2nd RAI treatments of 6 months (range, 3 to 78) (Fig. 1A). The remission rate of the 2nd RAI therapy was 66% (152/230), which was significantly higher than that of the 1st RAI therapy (P<0.001) (Fig. 1B). Some patients with persistent GD after 1st RAI therapy received longterm ATD treatment. Delayed response was observed, and the remission was achieved in 42% (81/189) of patients (Supplemental Table S1). The remission rate of long-term ATD treatment was significantly lower than the 1-year remission rate of 2nd RAI therapy (P<0.001), and it was achieved at a median of 35 months (range, 25 to 53). After the 2nd RAI therapy, 78 (34%) patients did not achieve remission, and of them, 36 patients underwent a 3rd RAI therapy, of whom 61% (21/36) achieved remission within 1 year (Fig. 1A).
Rapid response to RAI in the second RAI therapy
To clarify the optimal time for assessing the clinical outcomes of each round of RAI therapy, the intervals until ATD discontinuation and the start of LT4 replacement were explored. Compared to the 1st RAI therapy, the 2nd RAI therapy showed significantly shorter intervals until ATD discontinuation (median 1.3 months [0 to 10.2] vs. 2.3 months [0 to 11.8], P<0.001) and the start of LT4 replacement (median 2.5 months [0.9 to 76.1] vs. 4.4 months [0.4 to 11.8], P=0.001). Kaplan-Meier curves showed that 80% of patients who achieved remission discontinued ATD within 4.2 and 2.3 months after 1st and 2nd RAI therapies, respectively (Fig. 2A). Additionally, 80% of those who achieved remission started LT4 within 17.0 and 5.5 months after the 1st and 2nd RAI therapies, respectively (Fig. 2B). The time to discontinue ATD (1.7 months) or start LT4 after the 3rd RAI therapy (3.5 months) was similar to those after the 2nd RAI therapy.
Predictors of remission after second RAI therapy
For the 1st RAI therapy (n=815), univariable logistic regression analysis showed that female sex, a shorter time interval after diagnosis, a smaller goiter size, a smaller dosage of ATD, a higher pre-RAI TSH level, and a lower pre-RAI TSHR antibody level were associated with a higher likelihood of remission (Table 1). However, in the multivariable logistic regression analysis, only a shorter time (≤4 years) from diagnosis to the 1st RAI therapy and smaller goiter size (<90 g) were significant predictors of remission (Table 1).
Next, for the 2nd RAI therapy, the characteristics of 152 patients who achieved remission 1 year after the 2nd RAI therapy were compared with 78 patients with persistent GD even after the 2nd RAI therapy (Supplemental Table S2). Patients with remission had a longer time interval between the 1st and 2nd RAI therapies (12±12 months vs. 8±7 months, P=0.002) and smaller goiter size than those with persistent GD (Supplemental Table S2). To determine whether the response to the 1st RAI therapy predicted remission after the 2nd RAI therapy, the dosage and discontinuation of ATD were investigated for 6 months after the 1st RAI therapy. Patients with remission were more likely to have discontinued ATD treatment for over 2 months (36% vs. 21%, P=0.023) and to have used a lower ATD dosage (12±7 mg vs. 14±7 mg, P=0.023). Most patients (89%) used methimazole and 9% used propylthiouracil, and types of ATD were not different between remission and persistent group (89% vs. 90%, P=0.807). The remission group had a higher pre-RAI TSH level (1.58±8.43 μIU/mL vs. 0.10±0.25 μIU/mL, P=0.036) and a lower pre-RAI free T4 level (2.25±1.25 ng/dL vs. 2.89±2.14 ng/dL, P=0.016) (Supplemental Table S2). In the univariable logistic regression analysis, a longer time interval (≥12 months) between the 1st and 2nd RAI therapies, smaller goiter size (<90 g), ATD discontinuation (≥2 months), and a higher TSH level (≥0.1 μIU/mL) were significantly associated with remission (Table 2). However, older age (>60 years) was associated with a higher likelihood of persistence. Multivariable logistic regression analysis showed that age, time interval between consecutive RAI therapies, goiter size, and ATD discontinuation were significant predictors of remission after the 2nd RAI therapy (Table 2).
ATD dose reduction effect of second RAI therapy in patients with persistent GD
Even if RAI therapy fails and GD persists, RAI therapy can reduce the dosage of ATD. In patients with persistent disease after RAI therapy, 1st RAI therapy and 2nd RAI therapy significantly reduced 8.4 and 5.1 mg of ATD over 12 months, respectively (both P<0.01) (Fig. 3A). Next, we compared the clinical outcomes of two groups that failed 1st RAI therapy: 189 patients who maintained ATD treatment without 2nd RAI therapy (2nd RAI(−) group) and 78 patients who received 2nd RAI therapy but failed (2nd RAI(+) group). After 1st RAI therapy, a higher dosage of ATD was required in the 2nd RAI(+) group than in the 2nd RAI(−) group (18±8 mg vs. 11±7 mg, P<0.001) (Fig. 3B). However, the 2nd RAI therapy reduced the dosage of ATD in the 2nd RAI(+) group to a comparable level to that of the 2nd RAI(−) group (Fig. 3B).
DISCUSSION
In the present study, the 2nd RAI therapy showed a higher remission rate (66%) and a shorter time to remission, mostly within 4 months, compared with the 1st RAI therapy. Even in patients who did not achieve remission after the 2nd RAI therapy, the 2nd RAI therapy led to ATD dose reduction. Therefore, repeated RAI therapy can be an effective therapeutic choice in patients with persistent GD after the 1st RAI therapy, especially in those with a small goiter size, a long time interval from the 1st RAI therapy, and a history of ATD discontinuation after the 1st RAI therapy.
The remission rate after the 1st RAI therapy in this study was 48%, which is lower than the remission rate of 74% to 81% in a previous randomized controlled study [13]. This may be because RAI therapy was performed as a second-line treatment. A meta-analysis showed that ATD use before RAI therapy had 1.48 to 2.05-fold higher risk of RAI treatment failure [14,15]. Park et al. [19] also reported that the remission rate of RAI therapy as a second-line treatment was 63%. Previous epidemiological studies with higher proportion of RAI therapy as a second-line treatment have tended to report worse remission rates than other studies (56%–79% vs. 83%–88%) [20-23].
Few studies have investigated the clinical outcomes of the 2nd RAI therapy separately. A strength of this study is that a large number of GD patients who received repeated RAI therapies were recruited, and the treatment response of 2nd RAI therapy was compared with that of 1st RAI therapy. The remission rate of the 2nd RAI therapy (66%) was significantly higher than that of the 1st RAI therapy (48%) or long-term ATD treatment (42%); thus, repeated RAI therapy can be a good therapeutic strategy for patients who fail the 1st RAI therapy. Although RAI therapy is effective for GD, RAI has some concerns such as the risk of exacerbating Graves’ ophthalmopathy and a potential radiation hazard [4,24,25]. Therefore, it is necessary to individualize which treatment to choose. Next, the time from RAI therapy to achieving remission was shorter after 2nd RAI therapy than after the 1st RAI therapy, suggesting that the clinical outcomes of repeated RAI therapy can be assessed more promptly. The American Thyroid Association guideline recommends considering repeated RAI if GD persists after 6 months following the 1st RAI therapy [4]. Indeed, the cumulative remission rates plateaued after 6 months following the 1st RAI therapy in this study. Meanwhile, remission was achieved earlier in 2nd RAI therapies, as approximately 80% of patients were expected to stop ATD within 2.3 months. Therefore, the treatment response of repeated RAI therapy needs to be assessed before 4 months, and an earlier plan for LT4 replacement should be followed to maintain the quality of life of those patients [26].
Many previous researchers have made efforts to predict the success of the 1st RAI therapy. A recent meta-analysis reported that male sex, a longer time from GD diagnosis to RAI therapy (>6 months), previous ATD use, a higher free T4 level, a higher 24-hour RAIU (≥60%), and a larger thyroid volume (>35 mL) increased the risk of RAI therapy failure [15]. In this study, a longer time from GD diagnosis to RAI therapy and a larger goiter size were also significantly associated with failure of the 1st RAI therapy. In both the 1st and 2nd RAI therapies, goiter size assessed by physical examination was a strong predictor of remission. It suggested that the assessment of goiter size through physical examination can make a sufficiently significant prediction for the success of RAI therapy. However, the predictors of the 1st and 2nd RAI therapies were not always the same. The time from diagnosis to RAI therapy, a significant predictor of remission after the 1st RAI therapy, did not predict remission after the 2nd RAI therapy. Instead, a long interval between the 1st and 2nd RAI therapies (>12 months) was associated with an increased likelihood of remission (odds ratio, 3.82) (Table 2). Stabilizing GD using an ATD before 2nd RAI therapy may be beneficial for achieving remission. Even if the initial ATD treatment fails, the remission may be achieved in the second or third ATD treatment [27]. Therefore, the long-term use of ATD before 2nd RAI therapy may improve the GD itself and contribute to the success of the 2nd RAI therapy. In addition, a good response to the 1st RAI therapy, allowing the ATD to be discontinued for over 2 months, was associated with remission (odds ratio, 2.86) (Table 2). In other words, patients who were more responsive to the 1st RAI therapy were more likely to achieve remission after the 2nd RAI therapy. In this study, pre-RAI TSH was not associated with the remission in multivariable logistic regression analysis. Some patients (n=16) showed higher TSH than normal range just before RAI. In these patients, as GD worsened, ATD dose was increased, and TSH became higher than normal range. However, even if pre-RAI TSH levels of these patients were corrected, pre-RAI TSH level was not associated with the remission (odds ratio, 1.84; 95% confidence interval, 0.82 to 4.13; P=0.140).
This study has the limitations inherent to retrospective studies. The initial thyroid hormone or anti-TSHR antibody levels at the time of GD diagnosis could not be collected and analyzed, because of the nature of a tertiary referral hospital, although previous studies have reported that free T4 or TSHR antibody levels at the time of diagnosis predicted remission [15,21,28]. Instead, the levels of free T4, TSH, and TSHR antibody just before RAI therapy were used in the analysis, but they did not predict remission after RAI therapy. In addition, the RAI dose was not calculated based on the size of the thyroid and its ability to absorb 131I, but a fixed dose (15 mCi) was used empirically according to the doctor’s judgment. Therefore, it would be difficult to evaluate the effect of the RAI dose on remission. However, the RAI dose was not associated with the success of RAI therapy in previous studies [15].
In conclusion, repeated RAI therapy can be a good therapeutic option in patients with persistent GD after the 1st RAI therapy, especially in patients who have a small goiter size and show a good response to the 1st RAI therapy. LT4 replacement therapy should be prepared earlier after repeated RAI therapy than after the 1st RAI therapy (i.e., within 4 months).
XML Download